Login to Your Account



Arog's crenolanib vs. AML, GIST, and more

By Randy Osborne
Staff Writer

Tuesday, November 22, 2016

Privately held Arog Pharmaceuticals Inc. won orphan drug status in Europe for crenolanib to treat AML and soft-tissue sarcoma.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription